Skip to main content
Dryad logo

Data from: Piceatannol attenuates RANKL-induced osteoclast differentiation and bone resorption and promotes caspase3-mediated apoptosis of mature osteoclasts

Citation

Yan, Liuliu et al. (2019), Data from: Piceatannol attenuates RANKL-induced osteoclast differentiation and bone resorption and promotes caspase3-mediated apoptosis of mature osteoclasts, Dryad, Dataset, https://doi.org/10.5061/dryad.df19750

Abstract

Osteoclasts are multinuclear giant cells that have unique ability to degrade bone. The search for new medicines that modulate the formation and function of osteoclasts is a potential approach for treating osteoclast-related bone diseases. Piceatannol (PIC), a natural organic polyphenolic stilbene compound found in diverse plants with a strong antioxidant and anti-inflammatory effect. However, the effect of PIC on bone health has not been scrutinized systematically. In this study, we used RAW264.7, a osteoclast lineage cells of murine macrophages, to investigate the effects and the underlying mechanisms of PIC on osteoclasts . Here, we demonstrated that PIC treatment ranging from 0 to 40μM strongly inhibited osteoclast formation and bone resorption in a dose-dependent manner. Furthermore, the inhibitory effect of PIC was accompanied by the decrease of osteoclast-specific genes. At the molecular level, PIC suppressed the phosphorylation of c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK1/2), NF-κB p65, IκBα and AKT. Besides, PIC promoted the apoptosis of mature osteoclasts by inducing caspase-3 expression. In conclusion, our results suggested that PIC inhibited RANKL-induced osteoclastogenesis and bone resorption by suppressing MAPK, NF-κB and AKT signaling pathways and promoted caspase3-mediated apoptosis of mature osteoclasts, which might contribute to the treatment of bone diseases characterized by excessive bone resorption.

Usage Notes